NXTM - Nxstage Medical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.30
+0.13 (+0.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close29.17
Open29.20
Bid28.41 x 900
Ask29.98 x 1800
Day's Range29.07 - 29.35
52 Week Range23.17 - 29.35
Volume731,012
Avg. Volume662,459
Market Cap1.954B
Beta (3Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Markit8 days ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for NXTM with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting NXTM. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NXTM totaled $1.90 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 4 Healthcare Stocks Likely to Beat Estimates in Q4
    Zacks16 days ago

    4 Healthcare Stocks Likely to Beat Estimates in Q4

    An aging population, prevalence of chronic health conditions and greater utilization of healthcare services should drive the industry's growth, partly offset by an increase in expenses.

  • Reuters18 days ago

    FMC extends deadline for NxStage deal until Aug. 6 due to U.S. government shutdown

    Germany's Fresenius Medical Care (FMC) said on Tuesday it had agreed to extend the deadline for its planned $2 billion takeover of U.S. home dialysis equipment maker NxStage Medical Inc until August 6. FMC said the extension had been agreed due to the recent U.S. government shutdown which interrupted the Federal Trade Commission's (FTC) ability to review the transaction.

  • GlobeNewswire19 days ago

    Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
    Zackslast month

    4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

    Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.

  • Is NxStage Medical, Inc. (NXTM) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is NxStage Medical, Inc. (NXTM) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from the more than 700 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30. The results of that effort will be put on display in this […]

  • NxStage Medical (NXTM) Beats Q3 Earnings and Revenue Estimates
    Zacks3 months ago

    NxStage Medical (NXTM) Beats Q3 Earnings and Revenue Estimates

    NxStage (NXTM) delivered earnings and revenue surprises of 150.00% and 0.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • NxStage Is Back to Making Money
    Motley Fool3 months ago

    NxStage Is Back to Making Money

    Patient investors are still waiting for news on the dialysis specialist's expected merger.

  • Will NxStage Medical (NXTM) Report Negative Earnings Next Week? What You Should Know
    Zacks3 months ago

    Will NxStage Medical (NXTM) Report Negative Earnings Next Week? What You Should Know

    NxStage (NXTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • NxStage Announces Significant Increase in Nx2me Connected Health® Platform Adoption
    PR Newswire4 months ago

    NxStage Announces Significant Increase in Nx2me Connected Health® Platform Adoption

    "We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr.  Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.

  • New Study Showcases Improved Survival With More Frequent Home Hemodialysis in Incident Dialysis Patients
    PR Newswire4 months ago

    New Study Showcases Improved Survival With More Frequent Home Hemodialysis in Incident Dialysis Patients

    Patients 20-44 years of age experienced 44% lower risk of death LAWRENCE, Mass. , Oct. 23, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing ...

  • New Data Demonstrates Significant Survival Benefit with More Frequent Hemodialysis Using the NxStage System One in Skilled Nursing Facility Setting
    PR Newswire4 months ago

    New Data Demonstrates Significant Survival Benefit with More Frequent Hemodialysis Using the NxStage System One in Skilled Nursing Facility Setting

    LAWRENCE, Mass., Oct. 18, 2018 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, announced new findings demonstrating significant survival benefit and lower cardiovascular hospitalization with more frequent home hemodialysis using the NxStage® System One™ within the skilled nursing facility setting. The data, developed in collaboration with Affiliated Dialysis Centers, LLC, will be presented by NxStage at the American Society of Nephrology (ASN) Kidney Week 2018 Annual Meeting on October 26th. Conference attendees can meet with NxStage representatives at booth 1841 to discuss the recent findings.

  • Why Fresenius Medical Care AG & Co. KGaA Is Tanking Today
    Motley Fool4 months ago

    Why Fresenius Medical Care AG & Co. KGaA Is Tanking Today

    Shares tumble after management dials back guidance. Here's what investors need to know.

  • NxStage Medical (NXTM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks5 months ago

    NxStage Medical (NXTM) Reports Q2 Loss, Tops Revenue Estimates

    NxStage (NXTM) delivered earnings and revenue surprises of 20.00% and 1.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?